Nuvectis Pharma reports positive preliminary data from NXP800 phase 1b trial in ovarian cancer (platinum-resistant ARID1a-mutated)

Nuvectis Pharma, Inc., a biopharmaceutical company, shared positive preliminary findings from a phase 1b trial of NXP800 for platinum-resistant ARID1a-mutated ovarian cancer. Fast Track Designation was granted by the FDA for this program. The ongoing trial, conducted across top clinical centres in the US and UK, showed encouraging initial efficacy data. Among four patients treated, one on 75 mg/day achieved an unconfirmed partial response (PR), and two on 50 mg/day showed stable disease (SD). Grade 4 thrombocytopenia occurred in three patients but was transient, prompting a management protocol to minimize dosing interruptions. No other Grade 3 haematological toxicities were reported, with mild to moderate gastrointestinal adverse events in all patients. NXP800, a GCN2 kinase activator, is also being studied for cholangiocarcinoma. Nuvectis Pharma aims to address unmet medical needs in oncology, with a focus on precision medicines like NXP800 and NXP900.